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ABSTRACT 
Background: Cyclic vomiting syndrome (CVS) is a functional gastrointestinal disorder 
(FGID) characterized by intermittent episodes of nausea and vomiting. Our aim was to report 
its prevalence and associated risk factors. 
Methods: Demographic, symptomatic and mood data were collected. Symptoms compatible 
with CVS were classified as per Rome III criteria. We recorded whether a diagnosis of CVS 
was considered in patients after negative investigations - “true” CVS. We compared 
demographics and association with other FGIDs in patients with and without “true” CVS. 
Key Results: 920 of 1002 patients completed questionnaire data. We found that of the 920 
patients, 112 (12.2%) had symptoms compatible with CVS. 51 of these 112 patients (45.5%) 
were found to have an organic cause for their symptoms, but 61 patients (54.5%) were 
deemed to have “true” CVS (prevalence = 6.6%). Common organic causes for symptoms 
compatible with CVS were gastro-esophageal reflux disease (31.4%), dysmotility (11.4%) 
and celiac disease (7.8%). Only 34.4% of patients with “true” CVS were asked about 
vomiting symptoms at their initial consultation, and a diagnosis of CVS was considered in 
only four (6.6%) of the 61 patients. “True” CVS was associated with younger age, female 
gender, tobacco smoking and presence of symptoms compatible with other FGIDs (P <0.01). 
Conclusions & Inferences: Prevalence of CVS in this outpatient gastroenterology adult 
population was 6.6%.  Identified risk factors included younger age, female gender, tobacco 
smoking and symptoms compatible with other FGIDs. The condition was considered as a 
possible diagnosis in <10% of patients who met the diagnostic criteria.  
Key words: Vomiting, prevalence, functional gastrointestinal disorders. 
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Key Points 
• Epidemiology of cyclic vomiting syndrome (CVS) in adults is poorly understood. Lack 
of recognition leads to diagnostic delay, although reasons for this are unclear. We 
examined these issues in adults in secondary care.    
• Approximately 7% of patients in secondary care met criteria for CVS. Symptoms of 
vomiting were poorly elicited. The diagnosis was considered in a minority. 
• Education of physicians likely to encounter patients with CVS is paramount to eliminate 
diagnostic delay, reduce financial burden and enable appropriate management.  
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BACKGROUND 
 
Cyclical vomiting syndrome (CVS) is a poorly understood functional gastrointestinal 
(GI) disorder, which is characterized by acute episodes of nausea and vomiting, followed by 
asymptomatic periods ranging anywhere from days to months. The condition was first 
reported in children over 50 years ago1, and therefore the symptomatology and epidemiology 
in pediatric populations is well-described.2-5 However, it is only in the last 20 or 30 years that 
it has been recognized that this disorder can also present for the first time in later life.6 The 
Rome IV criteria for the diagnosis of CVS in adults consists of at least three episodes of acute 
vomiting in the previous 12 months, lasting less than 1 week, with two episodes in the last 6 
months occurring at least 1 week apart, and the absence of vomiting between episodes, 
although there is a recognition that milder symptoms, such as nausea, may be present in 
between these episodes.7  
Despite the development of diagnostic criteria for CVS in adults, the condition 
remains under-recognized, even though vomiting itself is a common complaint, with up to 3% 
of individuals reporting it in cross-sectional surveys in the community.8 The average age of 
onset of symptoms of CVS in the adult population is 22 years, yet the average age of 
individuals at the time the diagnosis is made is 31 years.9 This substantial delay in diagnosis 
may be due to a lack of recognition of the condition, or a failure to ask pertinent questions 
when eliciting a clinical history.  
Although there are numerous case series of adult patients with CVS,10-14 the majority 
of these contain few patients, and therefore the epidemiology of CVS in adults remains poorly 
understood, with few true prevalence data. There is also a lack of studies reporting associated 
features or clinical risk factors for the condition. The aims of this study were therefore to 
estimate the prevalence of CVS in a large number of consecutive unselected referrals with GI 
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symptoms in secondary care, and to assess the degree to which the possibility of a diagnosis 
of CVS was considered, as well as to examine associated features in those meeting criteria for 
CVS, in order to better understand the epidemiology of the condition in adults.  
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MATERIALS AND METHODS 
 
Participants and Setting 
We recruited unselected, consecutive patients aged ≥16 years newly referred from 
primary care to secondary care for consideration of investigation of GI symptoms. All 
participants were approached in six of the medical gastroenterology outpatient clinics of 
Leeds Teaching Hospitals Trust, West Yorkshire, United Kingdom. The hospitals provide 
secondary care services to a local population of almost 800,000 people in the North of 
England. The only exclusion criteria were inability to read written English, as the study 
questionnaires were all self-administered.  
Potentially eligible subjects were given a study information sheet at their initial clinic 
visit, before consultation with a gastroenterologist. Following agreement to participate, 
written consent was gained from each person. The local ethics committee approved the study 
(reference 13/YH/0216). Recruitment commenced in January 2014, and continued through to 
December 2015. During the 2-year recruitment period the six involved clinics saw 
approximately 2200 new outpatient referrals. As the study was conducted in routine clinical 
practice, clinical decisions and pathways were not standardized; thus management decisions 
were based on the clinical expertise and opinion of the responsible gastroenterologist. We did 
not mandate a minimum panel of blood tests, or upper GI endoscopy and collection of biopsy 
specimens in all patients. However, all patients agreeing to participate were asked to complete 
standardized questionnaires detailed below. We have previously used this dataset to examine 
the performance of the Rome III criteria for irritable bowel syndrome (IBS),15 to validate a 
latent class model to predict a diagnosis of IBS,16 and to validate and modify a scoring system 
to predict need for random colonic biopsies to detect microscopic colitis in patients with 
chronic diarrhea.17 
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Data Collection and Synthesis 
 
Demographic, Symptom, Mood, and Somatization Data 
Demographic data were collected prospectively and entered into a standardized 
database; information included gender, age, height (in meters), and weight (in kilograms), 
from which body mass index (BMI) was calculated, tobacco and alcohol use, marital status, 
educational status, and ethnicity.  
Symptom data were collected prospectively at the initial clinic visit. The Rome III 
diagnostic questionnaire for adult functional GI disorders was used to collect data on GI 
symptoms.18 In addition to this, we recorded if vomiting symptoms were documented as 
present or absent by the physician in the clinical notes at the initial consultation, and if a 
diagnosis of CVS was considered by the responsible gastroenterologist in those patients who 
met the Rome III criteria for the condition. 
Mood data were also collected in these patients. We used the validated hospital 
anxiety and depression scale (HADS).19 This contains 14 questions; seven relating to anxiety 
and seven to depression. Each question is scored from 0 to 3, equating to a maximum score of 
21. A score of ≥8 was used to identify possible anxiety or depression.  
Somatization-type behavior was assessed using the validated patient health 
questionnaire-15 (PHQ-15).20 This uses 15 questions, each scoring from 0 to 2, assessing 
individual somatic symptoms giving a potential maximum score of 30. A score of ≥15 is the 
validated value to identify high levels of somatization.  
All questionnaire data were entered into a database by trained researchers who were 
not involved in the clinical care of the patient, thus ensuring assessors were blinded to 
symptom status. 
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Definition of CVS 
Symptoms compatible with a diagnosis of CVS were identified using the scoring 
system proposed by the validated Rome III questionnaire (Supplementary Table 1).18 The 
final diagnosis in each patient was obtained by accessing their clinical records, only after 
completion of all relevant investigations. A diagnosis of “true” CVS was applied to those 
individuals meeting the Rome III criteria after appropriate investigations had failed to reveal 
an organic cause of their symptoms, to the level of investigation deemed appropriate by the 
responsible gastroenterologist.  
 
Statistical Analysis 
We compared demographic data of those with “true” CVS with those of all other 
patients consulting with GI symptoms using a χ2 test for categorical data, and an independent 
samples t-test for continuous data, with a mean and standard deviation (SD). Due to multiple 
comparisons a 2-tailed P value of <0.01 was considered statistically significant for these 
analyses. All statistical analyses were performed using SPSS for Windows version 21.0 
(SPSS Inc., Chicago, IL, USA). 
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RESULTS 
Between January 2014 and December 2015 a total of 1002 patients consented to take 
part in the study; 638 were female (63.7%) and the mean age of included individuals was 54.4 
years (range 16-92 years). Of these patients, 920 (91.8%) provided complete questionnaire 
data (580 (63.0%) female, mean age 53.9 years (range 16 to 92 years)). In total, 112 (12.2%) 
of the 920 patients met the Rome III criteria for CVS (Figure 1). However, 51 (45.5%) of 
these patients had an organic diagnosis that would potentially explain their symptoms, after 
investigation to the level deemed appropriate by the responsible physician. The commonest or 
most notable of these are detailed in Table 1, and included erosive esophagitis in 16 patients 
(31.4%), confirmed dysmotility of the esophagus or stomach in six (11.8%), celiac disease in 
four (7.8%), peptic ulcer disease in three (5.9%), large hiatus hernia in three (5.9%), 
esophageal adenocarcinoma in one, and peritoneal metastases in one.   
 
Prevalence of “True” CVS 
The remaining 61 (54.5%) patients meeting Rome III criteria for CVS had no organic 
cause found to explain their GI symptoms, following investigation to a level deemed 
appropriate by the responsible gastroenterologist. These 61 patients were therefore defined as 
having “true” CVS, giving a prevalence in this secondary care population of 920 patients of 
6.6% (95% confidence interval 5.2% to 8.4%). Only 21 (34.4%) of these 61 patients had any 
documentation in their clinical notes as to whether vomiting was present or absent at their 
initial consultation. In addition, a diagnosis of CVS was considered in only four (6.6%) of 
these 61 patients with “true” CVS.  
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Features of Patients with “True” CVS 
Of the 61 patients deemed to have “true” CVS, 49 (80.3%) were female, and the mean 
age was 43.6 years. Comparison of those with “true” CVS with all other patients with GI 
symptoms consulting in secondary care revealed that those with true CVS were significantly 
younger (Table 2). In addition, there were statistically significant associations between the 
presence of “true” CVS and female gender, tobacco smoking, and never having married. The 
reporting of symptoms compatible with other Rome III-defined functional GI disorders, 
including functional belching, functional chest pain, functional nausea, post-prandial distress 
syndrome, IBS, chronic proctalgia, and proctalgia fugax was also more likely in those with 
“true” CVS. Anxiety and somatization scores were significantly higher among patients with 
“true” CVS, but not depression scores. Finally, there were significantly more individuals with 
high levels of somatization, and a trend towards more individuals with abnormal levels of 
anxiety.  
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DISCUSSION 
This study confirms that CVS is prevalent in an outpatient gastroenterology 
population, with almost 7% of patients seen in a secondary care clinic meeting the Rome III 
criteria. However, the condition remains under-recognized, with the diagnosis considered in 
only four (6.6%) of the 61 patients who met these criteria and who were felt to have “true” 
CVS. Common and notable organic explanations for symptoms in patients who were initially 
thought to have CVS prior to investigation included erosive esophagitis, esophageal or gastric 
dysmotility, celiac disease, peptic ulcer disease, and large hiatus hernia. In addition, one 
patient was found to have esophageal adenocarcinoma, and a second had peritoneal 
metastases. Younger age, female gender, tobacco smoking, and never having married were all 
associated with the presence of “true” CVS, anxiety and somatization scores were higher than 
in other patients with GI symptoms, although no statistically significant difference was seen 
in depression scores.  
We recruited a large number of unselected patients with GI symptoms in secondary 
care, and none of the physicians consulting in the six outpatient gastroenterology clinics we 
recruited from has a specialist interest in this area, meaning that our results are likely to be 
generalizable to other patients seen in outpatient gastroenterology clinics. We collected data 
concerning a wide range of demographic variables, other GI symptoms, and psychological 
health, using validated questionnaires, and all patients included were investigated to the level 
deemed to be appropriate by the responsible gastroenterologist, prior to a diagnosis of “true” 
CVS being applied.   
Weaknesses of the study include the fact that, although we recruited a large sample of 
patients, the actual number with “true” CVS was small, reflecting that this is a relatively 
uncommon condition, meaning that we may have lacked sufficient power to detect some 
genuine associations between CVS and demographics, lifestyle, symptoms compatible with 
Sagar et al. Page 13 of 26 
 
other functional GI disorders, and mood. In addition, >90% of the patients involved were 
White Caucasian, meaning that the results of this study cannot be generalized to other 
ethnicities. We did not mandate a standard level of investigation to exclude an organic cause 
for symptoms suggestive of CVS, due to the fact that the study was conducted in routine 
clinical practice. This meant there was no consistent diagnostic algorithm applied to patients 
to rule out possible organic causes of symptoms prior to a label of “true” CVS being applied. 
Finally, as studying the prevalence of, and risk factors for, CVS was not the original primary 
objective of this cross-sectional survey; we did not collect data routinely on other lifestyle 
choices known to be associated with CVS, such as cannabis use.21 
Studies from the pediatric literature suggest the prevalence of symptoms meeting 
criteria for CVS in children and adolescents in the general population are between 0.3% and 
1.9%,4, 22-26 as high as 6.1% in primary care populations,27 and 8% to 10% in a pediatric 
gastroenterology clinic.28 The prevalence in the latter two studies among children is similar to 
that observed in our study in adults. A study from Ireland estimated the incidence of the 
condition to be 3.15 per 100,000 children per year.3 However, CVS is an under-studied 
disorder in the adult population, and a literature search we conducted revealed no available 
data on the prevalence of the condition in adults in either the community, or among referral 
populations, and no studies reporting on risk factors for CVS.  
As well as estimating the prevalence of CVS in adult patients in secondary care, our 
study highlights a failure of gastroenterologists to consider a diagnosis of CVS in the 
outpatient clinic. Part of this lack of recognition may relate to a failure to ask pertinent 
questions in the clinical history, as evidenced by the fact that the presence or absence of 
vomiting as a symptom was recorded in only one-in-three clinical consultations with the 
patients in this study. Another possible explanation is the observation that symptoms 
compatible with CVS in our study overlapped with multiple other functional GI disorders, so 
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it may be that the responsible gastroenterologists were concentrating on other symptoms that 
they deemed as being more important, or of higher priority, during consultations with these 
patients. Whatever the reasons, the main findings of our study suggest a need for better 
recognition of CVS as a potential diagnosis in adult patients with vomiting. The various 
associations with symptoms of CVS we identified in this study may aid this, and reduce the 
current diagnostic delay often seen in these patients.   
There are other aspects of CVS that we have been unable to examine as part of this 
study. We did not address underlying pathophysiological mechanisms, another poorly studied 
area in CVS, although there have been a number of potential theories hypothesized 
previously. These include activation of the corticotrophin-releasing factor signaling system,29, 
30 abnormal gastric motility,12, 31 mitochondrial DNA mutations,32, 33 and other genetic factors 
including variants in the RYR2 gene, which is involved in stress-induced calcium channels in 
autonomic neurons,34 and polymorphisms in genes encoding endogenous cannabinoid and 
opioid receptors.35 In addition, we did not evaluate the subsequent management of these 
patients, an issue that has been highlighted in the literature as problematic for 
gastroenterologists,13 although we have reported data from our center regarding the treatment 
of CVS previously.36  
In conclusion, the prevalence of CVS among adult patients in secondary care 
gastroenterology clinics in this study was 6.6%, but the diagnosis was considered in fewer 
than one-in-ten individuals with typical symptoms, who had no structural explanation for 
these, and who likely had CVS. Education of gastroenterologists, and other physicians who 
are likely to encounter such patients, including those in primary care and the emergency 
department, is paramount in order to eliminate the diagnostic delay seen in adults, and to 
reduce the financial impact of the condition on both primary and secondary healthcare 
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services, as well as to institute prompt and appropriate treatment in order to improve quality 
of life for these patients.  
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Table 1. Organic Diagnoses in Patients Meeting Rome III Criteria for CVS.  
 Number (%) 
(n = 51) 
Erosive esophagitis  16 (31.4%) 
Dysmotility 6 (11.8%) 
Celiac disease 4 (7.8%) 
Peptic ulcer disease 3 (5.9%) 
Large hiatus hernia 3 (5.9%) 
Esophageal adenocarcinoma 1 (2.0%) 
Peritoneal metastases 1 (2.0%) 
Other miscellaneous causes 17 (33.3%) 
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Table 2. Demographics and Baseline Characteristics of Patients with “True” CVS 
Compared with Patients with Other GI Symptoms not Meeting Criteria for CVS. 
 “True” CVS 
(n = 61) 
Other GI symptoms not 
meeting criteria for 
“true” CVS 
(n = 859) 
P value* 
Mean age in years (SD) 43.6 (17.6) 54.6 (17.3) <0.001 
Mean BMI (SD) 27.2 (8.6) 26.7 (8.1) 0.71 
Female gender (%) 49 (80.3) 531 (61.9) 0.004 
Tobacco use (%) 25 (41.0) 197 (23.5) 0.002 
Alcohol use (%) 32 (53.3) 480 (57.6) 0.52 
Marital status (%) 
Married or cohabiting 
Divorced or separated 
Never Married 
Widowed 
 
25 (42.4) 
9 (15.3) 
22 (37.3) 
3 (5.1) 
 
490 (59.3) 
102 (12.3) 
150 (18.1) 
85 (10.3) 
 
 
 
 
0.002 
University graduate or postgraduate 
education (%) 
14 (28.0) 161 (20.5) 0.28 
White Caucasian ethnicity (%) 54 (90) 777 (91.6) 0.84 
Globus (%) 0 (0) 28 (3.3) 0.15 
Functional heartburn (%) 19 (33.9) 209 (25.0) 0.14 
Functional belching (%) 24 (43.6) 181 (21.9) <0.001 
Functional chest pain (%) 6 (10.5) 22 (2.7) <0.001 
Functional nausea (%) 14 (23.0) 90 (10.6) 0.003 
Epigastric pain syndrome (%) 3 (5.0) 18 (2.1) 0.15 
Postprandial distress syndrome (%)  34 (63.0) 253 (31.5) <0.001 
Functional abdominal pain (%) 2 (3.4) 15 (1.8) 0.39 
IBS (%) 28 (54.9) 186 (23.6) <0.001 
Functional constipation (%) 5 (9.1) 86 (10.8) 0.68 
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Functional bloating (%) 2 (3.5) 34 (4.2) 0.79 
Chronic proctalgia (%) 11 (20.0) 32 (4.1) <0.001 
Proctalgia fugax (%) 25 (45.5) 179 (22.8) <0.001 
HADS anxiety categories (%) 
Normal 
Borderline 
Abnormal  
 
21 (40.4) 
9 (17.3) 
22 (42.3) 
 
428 (56.6) 
145 (19.2) 
183 (24.2) 
 
 
 
0.01 
Mean HADS anxiety scores (SD) 5.7 (4.1) 4.6 (4.2) 0.04 
HADS depression categories (%) 
Normal 
Borderline 
Abnormal  
 
45 (73.8) 
10 (16.4) 
6 (9.8) 
 
680 (79.2) 
91 (10.6) 
88 (10.2) 
 
 
 
0.37 
Mean HADS depression scores (SD) 9.2 (5.1) 7.1 (4.7) 0.008 
High level of somatization (%) 29 (64.4) 126 (18.8) <0.001 
Mean PHQ-15 scores (SD) 15.6 (5.0) 9.7 (5.5) <0.001 
*P value for independent samples t-test for continuous data and Pearson χ2 for comparison of 
categorical data. 
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FIGURE LEGENDS 
Figure 1. Flow of Study Participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1002 consecutive 
patients with GI 
symptoms 
enrolled 
920 (91.8%) 
patients provided 
complete CVS 
symptom data 
82 patients did not 
provide complete 
CVS symptom 
data 
112 (12.2%) 
patients met 
Rome III criteria 
for CVS 
808 (87.8%) 
patients did meet 
Rome III criteria 
for CVS 
61 (54.5%) 
patients had “true” 
Rome III CVS 
after investigation 
51 (45.5%) 
patients had 
organic disease 
after investigation 
